Experts Develop Impact-TD Scale to Assess Tardive Dyskinesia’s Daily Impact
A consensus panel of nine experts developed the Impact-TD scale to assess how tardive dyskinesia (TD) affects daily functioning. This scale addresses the lack of a standardized, clinician-rated tool for evaluating TD’s impact on patients’ lives.
Managing VMAT2 Inhibitor Side Effects for Tardive Dyskinesia
At the 2021 Psych Congress Regionals, Dr. Rakesh Jain discussed the symptoms of tardive dyskinesia and provided updates on treatments, focusing on VMAT2 inhibitors. He addressed common side effects of the FDA-approved VMAT2 inhibitors, valbenazine and deutetrabenazine, and offered strategies for managing these side effects.
Self-Care Strategies to Alleviate Tardive Dyskinesia Symptoms: Stress Reduction, Lifestyle Hacks, and Support
To minimize the symptoms of tardive dyskinesia (TD), stress reduction is key. Self-care gives those impacted by TD the mental and physical energy needed to cope with the many challenges of living with its symptoms.
Expert Panel Sets Guidelines for Assessing Tardive Dyskinesia Impact
Tardive dyskinesia (TD) is a movement disorder causing involuntary movements that severely impact patients’ physical, cognitive, and psychosocial functioning. Despite its significant effects, routine clinical practice often lacks measures to assess TD’s functional impact.
Coping with Tardive Dyskinesia: Strategies for Managing Symptoms and Enhancing Well-Being
Living with tardive dyskinesia (TD) presents challenges, from the distressing symptoms to the impact on daily life. Though symptoms like involuntary movements can be disruptive and self-consciousness-inducing, they might not be as noticeable to others as feared. Developing coping techniques and seeking support from mental health professionals can help navigate life with TD. Early detection and treatment are crucial, with medications like valbenazine and deutetrabenazine offering hope. Keeping a symptom diary can aid in monitoring progress and communicating effectively with healthcare providers. Prioritizing sleep and stress management can also alleviate symptoms, emphasizing self-care strategies to improve overall well-being.
Exploring the Genetic Factors in Tardive Dyskinesia Development and Management
The development of tardive dyskinesia (TD) is influenced by various factors including the type of antipsychotic, dose, duration of treatment, and individual genetic susceptibility. Studies have highlighted the role of genetic variations influencing the pharmacokinetics and pharmacodynamics of drugs, such as variations in dopamine, serotonin, and cannabinoid receptors, oxidative stress factors, and certain enzymes and transporters like CYP isoenzymes. Understanding these genetic factors is crucial as they contribute to the variability in drug metabolism and response, affecting both the efficacy and the adverse effects of antipsychotics.
Understanding and Managing Tardive Dyskinesia and Dystonia: Symptoms, Causes, and Treatments
This article covers symptoms, causes, and treatments for tardive dyskinesia and dystonia, both triggered by medications used for mental disorders, especially antipsychotics. Tardive dyskinesia results in involuntary facial movements, while dystonia causes sustained muscle contractions, often affecting the head and neck. While tardive dyskinesia develops gradually and may persist after medication cessation, dystonia can onset rapidly and stem from various causes including infections, tumors, or genetic factors.
The Extensive Impact of Tardive Dyskinesia Physically, Psychologically, and Socially
Researchers of a study assessed the multifaceted impact of tardive dyskinesia (TD) on patients through an online survey that took place from April 2020 to June 2021. Participants, who were diagnosed with TD and associated conditions like schizophrenia, bipolar disorder, or major depressive disorder, evaluated the impact of TD on their physical, psychological, and social functioning using Likert scales. They also completed the Work Productivity and Activity Impairment Questionnaire, providing insights into TD’s influence on their underlying psychiatric conditions.
Study Leverages Lean Six Sigma to Enhance Tardive Dyskinesia Management in Antipsychotic Treatment
In a study, researchers provided insights on identifying and treating tardive dyskinesia (TD), particularly in patients treated with antipsychotics. They emphasize the importance of recognizing risk factors for TD, regularly evaluating patients using standardized tools and criteria, and considering the most suitable treatment options for each patient. The study utilizes the Lean Six Sigma quality improvement model, involving defining, measuring, analyzing, improving, and controlling processes to enhance the understanding and management of TD.
Growing Interest in CBD for Tardive Dyskinesia Despite Limited Scientific Evidence
Authors of an article summarized information on cannabidiol (CBD), a major component of the cannabis sativa plant, and tardive dyskinesia (TD). The use of CBD for health conditions, including TD, is increasing in popularity in the United States.
